Chapter 19: Hepatitis and Liver Disease Flashcards
Hepatitis A
- Acute
- Fecal-Oral transmission
- Yes vaccine
- 1st line tx is supportive care
Hepatitis B
- Acute and Chronic
- Blood and body fluid transmission
- Yes vaccine
- 1st line tx PEG-INF or NRTI (tenofovir or entacavir)
Hepatitis C
-Acute and Chronic
-Blood and body fluid transmission
-No vaccine
-1st line tx for tx naïve: DAA combination
Other tx: DAA combo + RBV or
DAA combo + RBV + PEG-INF
DAA mechanisms: NS3/4A Protease Inhibitors
-previr
P for PI
Glecaprevir
Grazoprevir
Paritaprevir
Voxilaprevir
*PIG
protease inhibitors and grub (take with food)
DAA Mechanisms: NS5A Replication Complex Inhibitors
-asvir
A for NS5A
Elbasvir Ledipasvir Ombitasvir Pibrentasvir Velpatasvir
DAA Mechanism: NS5B Polymerase Inhibitors
-buvir
B for NS5B
Dasabuvir
Sofosbuvir
All DAAs boxed warning, warnings, side-effects
Boxed: Risk of reactivation of HBV; test all patients prior to starting DAA
Warning: for sofosbuvir containing regimes do not use amiodarone serious symptomatic bradycardia
SE: well-tolerated
Epclusa
sofosbuvir/velpatasvir
sofosbuvir monotherapy not recommended
administer in original container
avoid or minimize acid-suppressive therapy
Mavyret
Glecaprevir/pibrentasvir
Take with food
Tx for pan-genotypic (all 6 genotypes) for tx naïve pts
- Epclusa
- Mavyret
Tx for salvage therapy
- Mavyret
- Vosevi (sofosbuvir/velpatasvir/voxilaprevir)
Tx for 8 week therapy (select patients)
-Mavyret
Tx for HCV/HIV co-infection
- Epclusa
- Harvoni (sofosbuvir/ledipasvir)
- Mavyret
Tx for children with certain genotypes
- Solvadi (sofosbuvir) and Harvoni (age >=3 years)
- Epclusa (age >=6 years)
- Mavyret (age >=12 years)
Viekira Pak Dose and CI
Paritaprevir/ritonavir/ombitasvir qam
and
Dasabuvir bid with meals
CI: use with cyp3A4 substrates or inducers and use with ethinyl estradiol products
Viekir Pak Warnings
Hepatic decompensation/failure in patients with cirrhosis, increased LFTs, significant drug interaction potential
Zepatier CI, Warnings
Elbasvir/grazoprevir
CI: Strong inducers of cyp3A4
Warnings: increased LFTs, significant drug interaction potential
All DAA CI
Strong inducers of CYP3A4: carbamazepine, oxcarbezapine, phenobarbitol, phenytoin, rifampin, rifabutin, and St. John’s Wort
Harvoni, Epclusa, and Vosevi DI
Antacids, H2RAs, and PPIs can decrease concentrations of ledipasvir and velpatasvir
PPIs are not recommended with Epclusa
Viekira Pak DI
Strong inducers of CYP3A4 (carbamazepine, oxcarbezapine, phenobarbitol, phenytoin, rifampin, rifabutin, and St. John’s Wort)
ethinyl estradiol containing products, lovastatin, simvastatin